科研成果： 1.科研项目 选择性激活FGFR1发挥代谢调控作用FGF1改构体的分子设计与功能验证，国家自然科学基金（已结题）； 靶向胆汁淤积症的非促分裂型FGF19突变体的设计与开发，浙江省自然科学基金（已结题）； FGF1ΔHBS缓解糖尿病心肌肥厚的作用及机制研究，宁波市自然科学基金（在研）。 2.所获成果（包括科研成果奖、专利、专著等） 3.发表论文（具有代表性的5篇） [1] Celastrol alleviated acute kidney injury by inhibition of ferroptosis through Nrf2/GPX4 pathway. Minling Pan*, Zhen Wang*, Yiyi Wang*, Xianqin Jiang, Yali Fan, Fanghua Gong#, Yunpeng Sun#, Dezhong Wang#. Biomedicine & Pharmacotherapy. 2023 Oct:166:115333. [2] FGF1ΔHBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression. Dezhong Wang*, Yuan Yin*, Shuyi Wang*, Tianyang Zhao*, Fanghua Gong, Yushuo Zhao, Beibei Wang, Yuli Huang, Zizhao Cheng, Guanghui Zhu, Zengshou Wang, Yang Wang, Jun Ren, Guang Liang#, Xiaokun Li#, Zhifeng Huang#. Signal Transduction and Targeted Therapy. 2021 Mar 24;6(1):133. [3] PPARγ Mediates the Anti-Epithelial-Mesenchymal Transition Effects of FGF1ΔHBS in Chronic Kidney Diseases via Inhibition of TGF-β1/SMAD3 Signaling. Dezhong Wang*, Tianyang Zhao*, Yushuo Zhao*, Yuan Yin, Yuli Huang, Zizhao Cheng, Beibei Wang, Sidan Liu, Minling Pan, Difei Sun#, Zengshou Wang#, Guanghui Zhu#. Frontiers in Pharmacology. 2021 Jun 3;12:690535. [4] FGF1ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation. Dezhong Wang*, Mengyun Jin*, Xinyu Zhao*, Tianyang Zhao, Wei Lin, Zhengle He, Miaojuan Fan, Wei Jin, Jie Zhou, Lingwei Jin, Chao Zheng, Hui Jin, Yushuo Zhao, Xiaokun Li, Lei Ying, Yang Wang#, Guanghui Zhu#, Zhifeng Huang#. Cell Death & Disease. 2019 Jun 12;10(6):464. |
